DRIO earnings analysis
What we found in DRIO's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The supplied extract does not include the consolidated income statement, balance sheet, cash-flow statement, segment disclosures, or MD&A financial discussion, so current-quarter revenue, margins, EPS, cash flow, and balance-sheet trends cannot be assessed. Item 1A states that there were no material changes from the risk factors in the 2025 Form 10-K. The filing references the financial statements in Exhibit 101.1 and financing-related exhibits 4.1, 10.1, and 10.2, but provides no quantitative operating outlook in the supplied text.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Risk factors unchanged
- The company states in Item 1A that there have been no material changes to the risk factors disclosed in its Annual Report on Form 10-K for the year ended December 31, 2025. Existing risks therefore remain applicable, but the supplied filing text does not identify any newly added or expanded risk.
What they said about what is next.
No quantitative revenue or EPS outlook is included in the supplied 10-Q text; numeric outlook may be deferred to the earnings release or call.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 13, 2026
- DarioHealth released its Q1 2026 results reflecting a revenue decline of 17.3% year-over-year, amounting to $5,584k compared to $6,752k in Q1 2025. The company continues to face challenges with net losses of $8,249k,…
- 10-K · March 19, 2026
- DarioHealth positions itself as a vertically integrated whole‑person digital health platform combining FDA‑cleared hardware, AI trained on proprietary device data, and behavioral coaching, with B2B (employers, health…
- 10-Q · May 14, 2025
- DarioHealth reported Q1 revenue of $6,752,000, up from $5,758,000 in Q1 2024, with gross profit of $3,882,000 (57.5% margin). Operating loss narrowed to $9,409,000 from $17,855,000 a year ago, but net loss remained…
- 10-K · March 10, 2025
- DarioHealth positions itself as a whole-person digital health platform built from D2C roots and multiple acquisitions (~$525 million invested in acquired companies) with over 5 million users and more than 90 clinical…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing DRIO makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever